%20and%20Batch%20Production%20Records%20(BPR).png)
HanchorBio and WuXi Biologics Form Fusion Protein Pipeline Partnership
CRDMO WuXi Biologics and HanchorBio, a clinical-stage biotech company focusing on immunotherapies for oncology and autoimmune diseases, signed a collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
![HanchorBio Chairman Scott Liu (left) and WuXi Biologics CEO Chris Chen after signing the strategic partnership agreement. [HanchorBio]](https://www.genengnews.com/wp-content/uploads/2026/01/Strategic-Partnership-Between-Hanchorbio-and-WuXi-Biologics-1-2048x1152-1-300x169.jpg)
) platform.
By leveraging WuXi Biologics expertise in complex biologics and its quality systems, HanchorBio aims to shorten development timelines and maintain flexibility across multiple clinical programs, according to Scott Liu, founder, chairman, and CEO of HanchorBio, who adds that “this partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets.”
The post HanchorBio and WuXi Biologics Form Fusion Protein Pipeline Partnership appeared first on GEN - Genetic Engineering and Biotechnology News.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
